Lupin gets USFDA’s nod for antibiotic Solosec

18 Feb 2022 Evaluate

Lupin has received approval from US Food and Drug Administration (USFDA) for its supplemental New Drug Application (sNDA) for usage of its antibiotic Solosec in adolescents for treatment of both bacterial vaginal infection in females and sexually transmitted infection, trichomoniasis.  The USFDA has approved the company's sNDA to expand the use of Solosec in the treatment of bacterial vaginosis (BV) for female patients 12 years of age and older and in the treatment of trichomoniasis for all patients 12 years of age and above.

The supplemental adolescent approval enhances Solosec's strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV. Solosec is an oral antibiotic used to treat bacterial vaginosis in adult women and also in treating Trichomoniasis, a common sexually transmitted infection (STI), in adults.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2151.05 19.25 (0.90%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×